Key Highlights

  • EyePoint Pharmaceuticals shares plunged 67% to $4.87.
  • The Phase 3 LUGANO trial evaluating DURAVYU in wet AMD failed to meet its primary BCVA endpoint.
  • An ad hoc analysis excluding nine patients with unrelated vision loss demonstrated non-inferiority to aflibercept.
  • The market now awaits LUCIA data in Q4 2026 and a potential NDA submission in the first half of 2027.

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) shares plunged 67% to $4.87 after the company announced that its Phase 3 LUGANO trial evaluating DURAVYU in wet age-related macular degeneration failed to meet its primary best-corrected visual acuity endpoint.

What Happened

An ad hoc analysis excluding nine patients with unrelated vision loss demonstrated non-inferiority to aflibercept, alongside a 42% reduction in treatment burden and favorable safety.

Market Reaction

Shares plunged sharply as investors focused on the primary endpoint miss in the full dataset, despite the more favorable results in the ad hoc analysis excluding unrelated vision-loss patients.

Outlook

The market awaits LUCIA data in the fourth quarter of 2026 and a potential NDA submission in the first half of 2027, both of which represent the next major disclosed milestones for DURAVYU in wet AMD.